1-4 of 4
Marjolein van der Klift
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Francesca Gay, Wilfried Roeloffzen, Meletios A. Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Roberto Mina, Albert Oriol Rocafiguera, Eirini Katodritou, Ka Lung Wu, Paula Rodriguez Otero, Roman Hajek, Elisabetta Antonioli, Mark van Duin, Mattia D'Agostino, Joaquin Martinez-Lopez, Elena M. van Leeuwen-Segarceanu, Paola Tacchetti, Niels W.C.J. van de Donk, Katja Weisel, Luděk Pour, Jakub Radocha, Angelo Belotti, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Pieter Sonneveld, Mario Boccadoro, Annemiek Broijl
Journal: Blood
Blood (2023) 142 (Supplement 1): 4.
https://doi.org/10.1182/blood-2023-177546
Published: 2023
Journal Articles

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Clinical Trials & Observations
Lina van der Straten, Claudia A. M. Stege, Sabina Kersting, Kazem Nasserinejad, Julie Dubois, Johan A. Dobber, Clemens H. M. Mellink, Anne-Marie F. van der Kevie-Kersemaekers, Ludo M. Evers, Fransien de Boer, Harry R. Koene, John Schreurs, Marjolein van der Klift, Gerjo A. Velders, Ellen van der Spek, Hanneke M. van der Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F. M. Posthuma, Hein P. J. Visser, Ilse Houtenbos, Cecile A. M. Idink, Djamila E. Issa, Ellen C. Dompeling, Henk C. T. van Zaanen, J. Hendrik Veelken, Henriette Levenga, Lidwine W. Tick, Wim E. Terpstra, Sanne H. Tonino, Peter E. Westerweel, Anton W. Langerak, Arnon P. Kater, Mark-David Levin
Journal: Blood
Blood (2023) 142 (13): 1131–1142.
https://doi.org/10.1182/blood.2023020195
Published: 2023
Includes: Supplemental data
Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst, Carsten Niemann, Arnon P. Kater, Moritz Fürstenau, Julia Von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Marjolein van der Klift, Ulrich Jaeger, Henrik Frederiksen, Maria B.L. Leijs, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R. Koene, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus H.J. Van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek
Journal: Blood
Blood (2021) 138 (Supplement 1): 71.
https://doi.org/10.1182/blood-2021-146161
Published: 2021
Journal Articles

First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment

Iris de Weerdt, MD, Tom Hofland, MSc, Johan Dobber, Julie Dubois, Eric Eldering, PhD, Mehrdad Mobasher, MD MPH, Fransien Croon-de Boer, Mels Hoogendoorn, MD PhD, Gerjo A. Velders, PhD MD, Marjolein van der Klift, Mark-David Levin, MD PhD, Sabina Kersting, MDPhD, Sanne Tonino, MD PhD, Arnon P. Kater, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1860.
https://doi.org/10.1182/blood-2018-99-116283
Published: 2018